Shenzhou Cell announced that Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to conduct clinical trials on patients with moderate to severe hemophilia A or hemophilia B with or without inhibitors. SCT810 is a monoclonal antibody against tissue factor pathway inhibitors. It has now been approved for phase I/II clinical research. There is uncertainty about the results and timing of subsequent clinical trials, review and approval of this product, and it is expected that it will not have a significant impact on the company's operating performance in the short term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.